Indian pharma wrapped up November 2025 with serious velocity. Growth wasn’t just linear — it was driven by a new value engine powered by GLP-1s, chronic-care momentum, and a pricing mix shift that meaningfully elevated the industry’s baseline. Even using only public data, the signal is unmistakable: November marked a strategic pivot point for the Indian Pharmaceutical Market (IPM).
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
